Company News: Page (1) of 1 - 03/12/18 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook

Radius Health to Present at ENDO 2018 Including Results of the ACTIVExtend BMD Responder Analysis for TYMLOS™ (abaloparatide) Injection

(March 12, 2018)

WALTHAM, Mass., March 12, 2018 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS) a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative endocrine therapeutics in the areas of osteoporosis and oncology, today announced two presentations highlighting clinical data for TYMLOS™ (abaloparatide) injection at ENDO 2018, the Endocrine Society’s 100th Annual Meeting and Expo in Chicago, IL. The abstract titled: “Response Rates for Hip, Femoral Neck, and Lumbar Spine Bone Mineral Density (BMD) in Patients Treated with Abaloparatide Followed by Alendronate – Results from Phase 3 ACTIVExtend,” will be presented in an oral session at ENDO 2018. Radius will also present a poster titled, “Fracture and Bone Mineral Density Response by Baseline Risk in Patients Treated with Abaloparatide Followed by Alendronate–Results from Phase 3 ACTIVExtend.”



TYMLOS was approved by the U.S. Food and Drug Administration on April 28, 2017 for the treatment of postmenopausal women with osteoporosis at high risk for fracture and has demonstrated significant reductions in the risk of new vertebral and nonvertebral fractures.

The oral presentation will take place during the oral abstracts session titled “Osteoporosis, Vitamin D, and Mineral Metabolism”:

  • Response Rates for Hip, Femoral Neck, and Lumbar Spine Bone Mineral Density in Patients Treated with Abaloparatide Followed by Alendronate – Results from Phase 3 ACTIVExtend (Deal)

    Page: 1


    Related Keywords:

-->

Our Privacy Policy --- @ Copyright, 2015 Digital Media Online, All Rights Reserved